Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.50 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | F2 | P00734 | 5/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.58 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.58 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.58 |
| ▸ | C1S | P09871 | 2/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | APEX1 | P27695 | 1/20 | 0.58 |
| ▸ | F10 | P00742 | 1/20 | 0.56 |
| ▸ | F12 | P00748 | 1/20 | 0.56 |
| ▸ | F7 | P08709 | 1/20 | 0.56 |
| ▸ | F3 | P13726 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | PLAU | P00749 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3876947 | 0.97 | TP53 (0.63) | BLMTP53TSHRF2PRSS1 | |
| Iodide SCHEMBL7274597 | 0.95 | TP53 (0.60) | BLMTP53TSHRF2PRSS1 | |
| Hydrochloric Acid SCHEMBL8994023 | 0.93 | PARP15 (0.59) | BLMTP53TSHRF2PRSS1 | |
| SCHEMBL3442777 | 0.91 | WDR5 (0.68) | BLMTP53TSHRF2PRSS1 | |
| Benzamidine SCHEMBL10816513 | 0.88 | F2 (0.76) | BLMTP53TSHRF2PRSS1 | |
| Terephthalic Acid SCHEMBL7555569 | 0.87 | TSHR (0.71) | TP53TSHRF2PRSS1PRSS3 | |
| Hydrochloric Acid SCHEMBL30999366 | 0.84 | PRSS1 (0.78) | BLMF2PRSS1PRSS3PRSS2 | |
| Hydrochloric Acid SCHEMBL392375 | 0.84 | PRSS1 (0.78) | BLMF2PRSS1PRSS3PRSS2 | |
| Hydrochloric Acid SCHEMBL8652339 | 0.82 | F2 (0.61) | BLMTSHRF2PRSS1PRSS3 | |
| Hydrochloric Acid SCHEMBL1483999 | 0.82 | F2 (0.61) | BLMTSHRF2PRSS1PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119390614-A | Preparation method of nafamostat mesylate | 河北广祥制药有限公司 | 2025-02-07 | — | — | CN | claimed |
| CN-119143634-A | Preparation method of nafamostat mesylate | 北京诺康达医药科技股份有限公司 | 2024-12-17 | — | — | CN | claimed |
| CN-119143635-A | Method for preparing nafamostat mesylate | 北京诺康达医药科技股份有限公司 | 2024-12-17 | — | — | CN | claimed |
| CN-117185963-A | Preparation method of high-purity nafamostat mesylate | 华仁药业（日照）有限公司 | 2023-12-08 | — | — | CN | claimed |
| US-12610734-B2 | Organic-inorganic hybrid perovskites | CITY UNIVERSITY OF HONG KONG (CN) | 2026-04-21 | — | — | US | disclosed |
| CN-119390614-B | Preparation method of nafamostat mesylate | 河北广祥制药有限公司 | 2025-09-19 | — | — | CN | disclosed |
| US-20250113727-A1 | ORGANIC-INORGANIC HYBRID PEROVSKITES | CITY UNIVERSITY OF HONG KONG (CN) | 2025-04-03 | — | — | US | disclosed |
| CN-119390614-A | Preparation method of nafamostat mesylate | 河北广祥制药有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-119390614-A | Preparation method of nafamostat mesylate | 河北广祥制药有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-119371391-A | Aroyl compound and preparation method and application thereof | 河北医科大学 | 2025-01-28 | — | — | CN | disclosed |
| CN-119365034-A | Perovskite solar cell and preparation method thereof | 广东明阳薄膜科技有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-119143634-A | Preparation method of nafamostat mesylate | 北京诺康达医药科技股份有限公司 | 2024-12-17 | — | — | CN | disclosed |
| WO-1997024119-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997024122-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
| EP-0765660-A2 | Microcapsules comprising 2-piperazinone-1-acetic acid compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-04-02 | — | — | EP | disclosed |
| EP-0750913-A2 | Disaccharide containing freeze-dried preparation for pharmaceutical use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-01-02 | — | — | EP | disclosed |
| WO-1996033982-A1 | PIPERAZINONES USEFUL AS INHIBITORS OF PLATELET AGGREGATION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-10-31 | — | — | WO | disclosed |
| WO-1996020172-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED β-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | NIPPON STEEL CORPORATION (JP) | 1996-07-04 | — | — | WO | disclosed |
| US-5294713-A | Inhibiting cell adhesion | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-03-15 | — | — | US | disclosed |
| EP-0529858-A1 | 2-Piperazinone compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1993-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12610734-B2 | Organic-inorganic hybrid perovskites | CHN2, AR, H1-2 | CA2 55/4885DRD1 1247/4885BLM 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.